Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in three critically ill patients suffering from severe, multi-organ complications induced by COVID-19 infection. The report was published today in the journal “Frontiers in Medicine.” The peer-reviewed article demonstrates the first use of an amniotic fluid-derived extracellular vesicles biologic as a safe and potentially efficacious therapeutic treatment for respiratory failure induced by COVID-19 infection.
“We are proud to share that ‘Frontiers in Medicine’ has published our case report on the exciting results of our Zofin treatment for respiratory failure induced by COVID-19 infection. We look forward to continuing to research Zofin in COVID-19 patients through our clinical trials,” said Albert Mitrani, CEO of Organicell.
“I am pleased to see that our research and development is translating into clinical settings. This case report helps demonstrate the safety, accessibility, and feasibility of Zofin for res...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).